Feb 12, 2026 07:01AM INmune Bio receives FDA alignment on phase 2b/3 trial design for alzheimer's drug

Feb 10, 2026 08:04AM INmune Bio submits CORDStrom pre-application to UK regulators for RDEB

Jan 27, 2026 09:25AM INmune Bio outlines 2026 milestones for CORDStrom and XPro programs

Oct 30, 2025 04:23PM INmune Bio, Inc. (INMB) Tops Q3 EPS by 9c

Aug 7, 2025 05:44PM INmune Bio, Inc. (INMB) Misses Q2 EPS by 65c

Aug 4, 2025 12:13PM Raymond James Reiterates Market Perform Rating on INmune Bio Inc. (INMB)

Aug 4, 2025 08:14AM INmune Bio completes prostate cancer trial, meets endpoints

Jun 30, 2025 04:37PM BTIG Downgrades INmune Bio Inc. (INMB) to Neutral

Jun 30, 2025 04:01PM Lucid Capital Markets Downgrades INmune Bio Inc. (INMB) to Neutral

Jun 30, 2025 02:24PM INmune Bio (INMB) call put ratio 1 call to 1.7 puts with a focus on July 2.5 put as share price down 59.9%

Jun 30, 2025 01:49PM Raymond James Downgrades INmune Bio Inc. (INMB) to Market Perform

Jun 30, 2025 10:36AM Increasing unusual call option volume: CFG INMB KBE TRIP TAP JNPR FEZ VNET PUBM JOBY NEXT FLNC

Jun 30, 2025 07:30AM INmune Bio (INMB) Reports Key Findings from Phase 2 MINDFuL Trial of XPro

Jun 27, 2025 12:16PM INmune Bio (INMB) Announces Approximately $19 Million Registered Direct Offering

Jun 26, 2025 04:42PM After-hours movers: Nike, American Outdoor Brands and more

Jun 26, 2025 04:01PM INmune Bio (INMB) to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th

Jun 24, 2025 10:47AM Increasing unusual put option volume: INMB MAIN URNM D FE ARRY EQX KBH ZION FLG WGS OZK ZETA COMM CAPR

Jun 23, 2025 10:53AM Increasing unusual put option volume: INMB GGAL CLBR BBWI LEU AR SCO EXEL ONDS

Jun 10, 2025 04:02PM INmune Bio (INMB): XPro Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense

Jun 4, 2025 06:18AM Lucid Capital Markets Starts INmune Bio Inc. (INMB) at Buy

May 8, 2025 04:14PM INmune Bio, Inc. (INMB) Tops Q1 EPS by 6c

Apr 16, 2025 07:01AM INmune Bio (INMB) Receives Favorable Patentability Opinion for CORDStrom Platform Technology

Apr 1, 2025 07:02AM INmune Bio (INMB) Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study

Mar 31, 2025 04:54AM Raymond James Reiterates Outperform Rating on INmune Bio Inc. (INMB)

Feb 12, 2025 07:03AM INmune Bio (INMB) Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer

Feb 12, 2025 05:12AM INmune Bio Inc. (INMB) PT Raised to $23 at Raymond James

Feb 11, 2025 06:53AM INmune Bio Inc. (INMB) PT Raised to $23 at Scotiabank

Feb 10, 2025 07:03AM INmune Bio (INMB) to Submit FDA Biologics License Application Seeking Approval of CORDStrom

Jan 28, 2025 10:26AM BTIG Reiterates Buy Rating on INmune Bio Inc. (INMB)

Jan 28, 2025 08:05AM INmune Bio (INMB) Expands INKmune Trial in Prostate Cancer to Veterans

Jan 28, 2025 06:31AM Rodman & Renshaw Starts INmune Bio Inc. (INMB) at Buy

Oct 31, 2024 04:12PM INmune Bio, Inc. (INMB) Misses Q3 EPS by 8c

Sep 26, 2024 08:01AM INmune Bio (INMB) Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

Sep 18, 2024 09:14AM Scotiabank Reiterates Sector Outperform Rating on INmune Bio Inc. (INMB)

Sep 18, 2024 06:22AM BTIG Reiterates Buy Rating on INmune Bio Inc. (INMB)

Sep 17, 2024 08:31AM INmune Bio (INMB) Reports Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial

Sep 13, 2024 08:31AM INmune Bio (INMB) Prices 2.34M Share Offering at $5.50/sh

Aug 22, 2024 07:38AM Scotiabank Starts INmune Bio Inc. (INMB) at Sector Outperform

Aug 2, 2024 04:03PM INmune Bio (INMB) Files $250M Mixed Shelf

Aug 1, 2024 04:51PM INmune Bio, Inc. (INMB) Tops Q2 EPS by 13c

Jul 29, 2024 09:00AM INmune Bio (INMB) Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients

Jul 23, 2024 08:45AM INmune Bio (INMB) Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune in the Journal for ImmunoTherapy of Cancer